|Bid||2.2000 x 1000|
|Ask||3.6000 x 800|
|Day's Range||2.8900 - 3.0000|
|52 Week Range||1.8000 - 6.1100|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
Lexaria Bioscience ( NASDAQ:LEXX ) Full Year 2022 Results Key Financial Results Net loss: US$7.27m (loss widened by 32...
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its patented DehydraTECH-CBD™ has demonstrated performance enhancements compared to one of the world's leading anti-seizure medications, Epidiolex®.
Kelowna, British Columbia – TheNewswire - November 29, 2022 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms ann...